BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coll RC, Schroder K, Pelegrín P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci 2022:S0165-6147(22)00083-9. [PMID: 35513901 DOI: 10.1016/j.tips.2022.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 El-sayed S, Freeman S, Bryce RA. A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome. Molecules 2022;27:6213. [DOI: 10.3390/molecules27196213] [Reference Citation Analysis]
2 Anderson FL, Biggs KE, Rankin BE, Havrda MC. NLRP3 inflammasome in neurodegenerative disease. Transl Res 2022:S1931-5244(22)00179-7. [PMID: 35952982 DOI: 10.1016/j.trsl.2022.08.006] [Reference Citation Analysis]
3 Sušjan-leite P, Ramuta TŽ, Boršić E, Orehek S, Hafner-bratkovič I. Supramolecular organizing centers at the interface of inflammation and neurodegeneration. Front Immunol 2022;13:940969. [DOI: 10.3389/fimmu.2022.940969] [Reference Citation Analysis]
4 Harrison D, Bock MG, Doedens JR, Gabel CA, Holloway MK, Lewis A, Scanlon J, Sharpe A, Simpson ID, Smolak P, Wishart G, Watt AP. Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00242] [Reference Citation Analysis]
5 Williams BM, Cliff CL, Lee K, Squires PE, Hills CE. The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy. Front Physiol 2022;13:907504. [PMID: 35755447 DOI: 10.3389/fphys.2022.907504] [Reference Citation Analysis]